Clinical trial of MetrioPharm's drug candidate MP1032 in COVID-19:
Mid 2021 the company initiated a clinical Phase II trial to treat COVID-19 patients with MP1032.The purpose of this Phase IIA study is to evaluate the efficacy and safety of MP1032 with standard of care (SoC) verses placebo with SoC in 120 hospitalized adults participants with moderate to severe coronavirus disease 2019 (COVID-19). The details of the current study design can be found here.
In preclinical studies, MetrioPharm's lead compound MP1032 demonstrated unique antiviral and anti-inflammatory activity. The results were published in the International Journal of Molecular Science.
MetrioPharm's drug candidate MP1032 has completed Phase II clinical testing in Psoriasis:
In October 2019, MetrioPharm AG successfully completed its Phase II trial of MP1032 in 155 psoriasis patients. The data confirmed the excellent safety profile of MP1032 and a trend towards clinical efficacy.
The MetrioPharm team is currently working on the detailed analysis of the collected data.
An outline of the study results can be found in the press release from 16/10/2019.
In March 2017, the phase IIa clinical trial in 44 patients with moderate-to-severe chronic plaque psoriasis was successfully completed:
The primary objectives of the study were to evaluate the safety and pharmacokinetics (PK) of twice daily 100 mg MP1032 in patients with moderate to severe plaque psoriasis. No serious side effects were observed in patients treated with MP1032.
Exploratory analysis of the drug's potential effect on PASI scores suggests a clinically relevant response in patients who entered the study with a PASI score of 10-20 and achieved appropriate MP1032 exposure levels.
In December 2015, the phase I clinical trial was successfully completed:
The results confirmed the preclinical data, which already indicated an outstanding safety profile. Even at 6 times the assumed therapeutically effective dose, no toxicity or intolerance was observed in the participants.